TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Benzinga Logo Benzinga By Vandana Singh
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Amgen announced Phase 2 study results for MariTide, its obesity treatment, showing that participants maintained weight loss achieved in part 1 for an additional 52 weeks on lower monthly or quarterly doses. The drug demonstrated up to 20% average weight loss in people with obesity without Type 2 diabetes and up to 17% in those with the condition. The treatment was well-tolerated with low incidence of nausea and vomiting, with no new safety signals observed. Amgen currently has six Phase 3 studies underway for MariTide across obesity and related conditions.

Insights
LZAGY   neutral

Listed as a key market player without specific performance indicators in the article


AMGN   positive

Amgen reported positive Phase 2 results for MariTide showing sustained weight loss with less frequent dosing, strong tolerability profile, and no new safety concerns. Analysts view it as a differentiated product with multibillion-dollar peak sales potential and maintain Outperform ratings. Stock showed positive momentum at time of publication.